BlackRock’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,236,951
| Closed | -$7.22M | – | 5783 |
|
|
2022
Q4 | $7.22M | Buy |
1,236,951
+410,760
| +50% | +$2.16M | ﹤0.01% | 3548 |
|
|
2022
Q3 | $5.54M | Buy |
826,191
+390,713
| +90% | +$2.37M | ﹤0.01% | 3712 |
|
|
2022
Q2 | $1.83M | Sell |
435,478
-12,470
| -3% | -$49.3K | ﹤0.01% | 4288 |
|
|
2022
Q1 | $1.51M | Sell |
447,948
-3,441
| -0.8% | -$10.9K | ﹤0.01% | 4505 |
|
|
2021
Q4 | $1.42M | Sell |
451,389
-268,584
| -37% | -$894K | ﹤0.01% | 4539 |
|
|
2021
Q3 | $2.35M | Buy |
719,973
+49,938
| +7% | +$175K | ﹤0.01% | 4257 |
|
|
2021
Q2 | $2.83M | Sell |
670,035
-1,657,183
| -71% | -$7.01M | ﹤0.01% | 4120 |
|
|
2021
Q1 | $11.6M | Buy |
2,327,218
+122,709
| +6% | +$992K | ﹤0.01% | 3482 |
|
|
2020
Q4 | $27.9M | Buy |
2,204,509
+387,055
| +21% | +$4.41M | ﹤0.01% | 2829 |
|
|
2020
Q3 | $17.8M | Sell |
1,817,454
-5,630
| -0.3% | -$55.5K | ﹤0.01% | 2924 |
|
|
2020
Q2 | $18.1M | Buy |
1,823,084
+69,624
| +4% | +$668K | ﹤0.01% | 2844 |
|
|
2020
Q1 | $15.5M | Buy |
1,753,460
+246,806
| +16% | +$2.43M | ﹤0.01% | 2736 |
|
|
2019
Q4 | $13.9M | Sell |
1,506,654
-235,168
| -14% | -$1.67M | ﹤0.01% | 3081 |
|
|
2019
Q3 | $10.2M | Buy |
1,741,822
+44,697
| +3% | +$474K | ﹤0.01% | 3203 |
|
|
2019
Q2 | $20.4M | Sell |
1,697,125
-27,587
| -2% | -$297K | ﹤0.01% | 2837 |
|
|
2019
Q1 | $20.8M | Buy |
1,724,712
+24,227
| +1% | +$357K | ﹤0.01% | 2724 |
|
|
2018
Q4 | $21.3M | Buy |
1,700,485
+23,076
| +1% | +$319K | ﹤0.01% | 2690 |
|
|
2018
Q3 | $24.9M | Buy |
1,677,409
+39,950
| +2% | +$629K | ﹤0.01% | 2745 |
|
|
2018
Q2 | $27.6M | Buy |
1,637,459
+42,347
| +3% | +$822K | ﹤0.01% | 2683 |
|
|
2018
Q1 | $36.5M | Sell |
1,595,112
-191,111
| -11% | -$4.25M | ﹤0.01% | 2445 |
|
|
2017
Q4 | $46.2M | Buy |
1,786,223
+649,808
| +57% | +$13.1M | ﹤0.01% | 2334 |
|
|
2017
Q3 | $16.8M | Buy |
1,136,415
+28,652
| +3% | +$416K | ﹤0.01% | 2897 |
|
|
2017
Q2 | $15.5M | Sell |
1,107,763
-4,523
| -0.4% | -$66.7K | ﹤0.01% | 2925 |
|
|
2017
Q1 | $19M | Buy |
1,112,286
+1,109,778
| +44,250% | +$13.3M | ﹤0.01% | 2788 |
|
|
2016
Q4 | $26K | Sell |
2,508
-250
| -9% | -$2.29K | ﹤0.01% | 3181 |
|
|
2016
Q3 | $28K | Buy |
2,758
+347
| +14% | +$3.79K | ﹤0.01% | 3206 |
|
|
2016
Q2 | $27K | Buy |
2,411
+1,245
| +107% | +$15.9K | ﹤0.01% | 3184 |
|
|
2016
Q1 | $16K | Buy |
+1,166
| New | +$16.8K | ﹤0.01% | 2966 |
|
|
2015
Q4 | – | Sell |
-400
| Closed | -$8K | – | 3538 |
|
|
2015
Q3 | $8K | Buy |
+400
| New | +$6.8K | ﹤0.01% | 2848 |
|
|
2015
Q1 | – | Sell |
-10,868
| Closed | -$145K | – | 3191 |
|
|
2014
Q4 | $145K | Sell |
10,868
-12,632
| -54% | -$163K | ﹤0.01% | 1612 |
|
|
2014
Q3 | $296K | Sell |
23,500
-24,900
| -51% | -$242K | ﹤0.01% | 1433 |
|
|
2014
Q2 | $489K | Hold |
48,400
| – | – | ﹤0.01% | 1335 |
|
|
2014
Q1 | $651K | Buy |
+48,400
| New | +$683K | ﹤0.01% | 1291 |
|
BlackRock's CNCE Position: Q1 2023 in Review
BlackRock sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 1,236,951 shares — an estimated $7.22M sold.
BlackRock first reported a position in CNCE in Q1 2014 and held it in 33 quarters. The position peaked at $46.2M in Q4 2017. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- BlackRock reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- BlackRock sold 1,236,951 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $7.22M.
- BlackRock first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 33 quarters.
- BlackRock's Concert Pharmaceuticals, Inc. position peaked at $46.2M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on BlackRock's 13F filing for Q1 2023, filed 12 May 2023.